Encapsulating peritoneal sclerosis

Encapsulating peritoneal sclerosis
Encapsulating peritoneal sclerosis
Specialty	Gastroenterology

Encapsulating peritoneal sclerosis (EPS) is a chronic clinical syndrome with an insidious onset that manifests as chronic undernourishment accompanied by sporadic, acute, or subacute gastrointestinal obstruction symptoms.^[1] Peritoneal dialysis is most commonly linked to encapsulating peritoneal sclerosis, especially when peritoneal dialysis is stopped.^[2] The diagnosis is verified by macroscopic and/or radiological observations of intestinal encapsulation, calcification, thickening of the peritoneum, or sclerosis.^[3]

Treatments that have been reported include the use of antifibrotic drugs like tamoxifen, immunosuppressant drugs like corticosteroids, nutritional support, and surgery to remove the fibrotic material.^[4]

^ Augustine, T.; Brown, P.W.; Davies, S.D.; Summers, A.M.; Wilkie, M.E. (January 16, 2009). "Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications". Nephron Clinical Practice. 111 (2). S. Karger AG: c149 – c154. doi:10.1159/000191214. ISSN 1660-2110. PMID 19147997.
^ Pepereke, Shingai; Shah, Ankur D; Brown, Edwina A (2023). "Encapsulating peritoneal sclerosis: Your questions answered". Peritoneal Dialysis International. 43 (2): 119–127. doi:10.1177/08968608221125606. ISSN 0896-8608. PMID 36189954. S2CID 252682098.
^ Kawaguchi, Y; Kawanishi, H; Mujais, S; Topley, N; Oreopoulos, D G (2000). "Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis". Peritoneal Dialysis International. 20 (4): S43 – S55. doi:10.1177/089686080002004S04. PMID 11098928.
^ Kawaguchi, Yoshindo; Saito, Akira; Kawanishi, Hideki; Nakayama, Masaaki; Miyazaki, Masanobu; Nakamoto, Hidetomo; Tranaeus, Anders (April 2005). "Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures". Peritoneal Dialysis International. 25 (4): S83 – S95. doi:10.1177/089686080502504S12. PMID 16300277.

[Clinical_Significance-1] Augustine, T.; Brown, P.W.; Davies, S.D.; Summers, A.M.; Wilkie, M.E. (January 16, 2009). "Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications". Nephron Clinical Practice. 111 (2). S. Karger AG: c149 – c154. doi:10.1159/000191214. ISSN 1660-2110. PMID 19147997.

[Your_questions_answered-2] Pepereke, Shingai; Shah, Ankur D; Brown, Edwina A (2023). "Encapsulating peritoneal sclerosis: Your questions answered". Peritoneal Dialysis International. 43 (2): 119–127. doi:10.1177/08968608221125606. ISSN 0896-8608. PMID 36189954. S2CID 252682098.

[Society_for_Peritoneal_Dialysis-3] Kawaguchi, Y; Kawanishi, H; Mujais, S; Topley, N; Oreopoulos, D G (2000). "Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis". Peritoneal Dialysis International. 20 (4): S43 – S55. doi:10.1177/089686080002004S04. PMID 11098928.

[Recommendations_on_the_management-4] Kawaguchi, Yoshindo; Saito, Akira; Kawanishi, Hideki; Nakayama, Masaaki; Miyazaki, Masanobu; Nakamoto, Hidetomo; Tranaeus, Anders (April 2005). "Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures". Peritoneal Dialysis International. 25 (4): S83 – S95. doi:10.1177/089686080502504S12. PMID 16300277.

[1]

[2]

[3]

[4]